Sakar Healthcare

What does Sakar Healthcare do?

Sakar Healthcare Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2004 and publicly listed since 2015, with recent quarterly net sales of 50 Cr and net profit of 6 Cr as of March 2025. Key metrics include a market cap of Rs 689 Cr, P/E of 39.00, and a debt-equity ratio of 0.26.

Overview: <BR>Sakar Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Sakar Healthcare Limited was incorporated as a Private Limited Company on March 26, 2004, and was converted into a Public Limited Company on March 27, 2015. The latest reported quarterly results indicate net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 50 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 6 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 689 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 39.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.26 <BR>Return on Equity: 6.14% <BR>Price to Book: 2.41 <BR><BR>Contact Details: <BR>Address: 10/13 Nr MN Desai Petrol Pump, Sarkhej Bavla Highway Changodar Gujarat : 382213 <BR>Tel: 91-2717-250477 <BR>Email: info@sakarhealthcare.com <BR>Website: http://www.sakarhealthcare.com

When is the next results date for Sakar Healthcare?

No Upcoming Board Meetings

Has Sakar Healthcare declared dividend?

No Dividend History Available

Who are the peers of the Sakar Healthcare?

Sakar Healthcare's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Management risk and growth vary among peers, with Sun Pharma and Cipla showing excellent metrics, while Sakar Healthcare has an average capital structure and a 1-year return of 0.00%.

Peers: Sakar Healthcare's peers are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Venus Remedies, Shukra Pharma., Nectar Lifesci., Medicamen Biotec, and Jenburkt Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average management risk is found at Venus Remedies, Shukra Pharma., Medicamen Biotec, and Jenburkt Pharma. Good management risk is noted at Divi's Lab., Torrent Pharma, and the rest. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is seen at Venus Remedies, Shukra Pharma., and the rest. Below Average growth is present at Divi's Lab., Torrent Pharma, Nectar Lifesci., Medicamen Biotec, and Jenburkt Pharma. Excellent capital structure is noted at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Divi's Lab., and Medicamen Biotec, while Good capital structure is found at Torrent Pharma and Shukra Pharma., and Average capital structure is observed at Sakar Healthcare, Venus Remedies, Nectar Lifesci., and Jenburkt Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Nectar Lifesci. has the lowest at -23.12%, with Sakar Healthcare's 1-year return at 0.00% being lower than both. Additionally, the six-month return is negative for Nectar Lifesci., Medicamen Biotec, and Jenburkt Pharma.

Who are in the management team of Sakar Healthcare?

As of March 2023, the management team of Sakar Healthcare includes Sanjay S Shah (Chairman & Managing Director), Aarsh S Shah (Joint Managing Director), Ritaben S Shah (Whole-time Director), and three Independent Non-Executive Directors: Shailesh B Patel, Prashant C Srivastav, and Hemendrakumar C Shah.

As of March 2023, the management team of Sakar Healthcare includes:<BR><BR>1. Sanjay S Shah - Chairman & Managing Director<BR>2. Aarsh S Shah - Joint Managing Director<BR>3. Ritaben S Shah - Whole-time Director<BR>4. Shailesh B Patel - Independent Non-Executive Director<BR>5. Prashant C Srivastav - Independent Non-Executive Director<BR>6. Hemendrakumar C Shah - Independent Non-Executive Director<BR><BR>These individuals play key roles in the governance and strategic direction of the company.

Who are the top shareholders of the Sakar Healthcare?

The top shareholders of Sakar Healthcare include Sanjay S Shah with 45.6%, Tata Capital Healthcare Fund II at 10.52%, and Foreign Institutional Investors holding 13.61%. Individual investors own 15.94%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Sakar Healthcare include the promoters, with Sanjay S Shah holding the largest share at 45.6%. Additionally, Tata Capital Healthcare Fund II is the highest public shareholder, owning 10.52%. Foreign Institutional Investors (FIIs) hold a combined 13.61% of the company through four different FIIs. Individual investors collectively own 15.94% of the shares. There are no pledged promoter holdings, and mutual funds do not currently hold any shares in the company.

How big is Sakar Healthcare?

As of 24th July, Sakar Healthcare Ltd has a market capitalization of 810.00 Cr, with recent net sales of 177.59 Cr and a net profit of 17.50 Cr. The balance sheet for March 2024 shows shareholder's funds of 262.33 Cr and total assets of 388.66 Cr.

As of 24th July, Sakar Healthcare Ltd has a market capitalization of 810.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sakar Healthcare reported Net Sales of 177.59 Cr and a Net Profit of 17.50 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 262.33 Cr and Total Assets of 388.66 Cr.

How has been the historical performance of Sakar Healthcare?

Sakar Healthcare has shown consistent growth over the past five years, with net sales increasing from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25, and profit after tax rising from 10.68 Cr to 17.50 Cr. The company's total assets also expanded significantly, from 115.04 Cr in Mar'20 to 415.26 Cr in Mar'25, indicating strong financial performance.

Answer:<BR>The historical performance of Sakar Healthcare shows a consistent growth trajectory in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Sakar Healthcare's net sales have increased from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25, demonstrating a strong upward trend. Total operating income has followed a similar pattern, rising from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25. The company's total expenditure has also grown, reaching 127.90 Cr in Mar'25, up from 72.14 Cr in Mar'21, primarily driven by rising raw material costs and employee expenses. Operating profit (PBDIT) has improved significantly, from 22.60 Cr in Mar'21 to 49.68 Cr in Mar'25, indicating enhanced operational efficiency. Profit before tax has increased from 13.23 Cr in Mar'21 to 21.53 Cr in Mar'25, while profit after tax has risen from 10.68 Cr in Mar'21 to 17.50 Cr in Mar'25. The company's earnings per share (EPS) have also shown growth, climbing from 6.84 in Mar'21 to 7.97 in Mar'25. On the balance sheet, total assets have expanded from 115.04 Cr in Mar'20 to 415.26 Cr in Mar'25, reflecting robust growth in shareholder's funds and reserves. Overall, Sakar Healthcare has demonstrated a solid financial performance with increasing revenues, profits, and asset growth over the years.

Is Sakar Healthcare overvalued or undervalued?

As of November 27, 2025, Sakar Healthcare is considered very expensive and overvalued, with a PE Ratio of 42.16 and other key ratios significantly higher than industry norms, indicating it may not be a favorable investment despite strong recent performance.

As of 27 November 2025, Sakar Healthcare's valuation grade has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios supporting this assessment include a PE Ratio of 42.16, an EV to EBIT of 30.26, and a Price to Book Value of 2.72, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Sakar Healthcare's PE Ratio is notably higher than Sun Pharma's 37.62 and Cipla's 22.67, which are categorized as expensive and attractive, respectively. Additionally, the company's EV to EBITDA of 17.37 is also elevated compared to the industry average. Despite a strong performance relative to the Sensex over the past year, with a return of 27.04% versus the Sensex's 7.99%, the current valuation suggests that Sakar Healthcare may not offer a favorable investment opportunity at this time.

Is Sakar Healthcare technically bullish or bearish?

As of November 27, 2025, the technical trend is bullish with strong indicators like MACD and moving averages supporting this view, despite some mildly bearish signals from Dow Theory and OBV on the weekly chart.

As of 27 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and the moving averages on the daily chart confirm a bullish trend. The Bollinger Bands indicate a bullish condition on the monthly and mildly bullish on the weekly. The KST is also bullish on both time frames. However, the Dow Theory shows a mildly bearish signal on the weekly but is mildly bullish on the monthly, and the OBV reflects a similar mildly bearish stance on the weekly while being mildly bullish on the monthly. Overall, the strength of the bullish trend is reinforced by the positive performance against the Sensex over multiple time frames, particularly the 1Y and 5Y returns.

Are Sakar Healthcare Ltd latest results good or bad?

Sakar Healthcare Ltd's Q3 FY26 results are strong, with a 62% revenue growth and a 126% increase in net profit, marking record highs. However, concerns about its high P/E ratio of 46.66 and modest ROE of 6.84% suggest caution for investors despite the impressive performance.

Sakar Healthcare Ltd's latest results for Q3 FY26 indicate a strong performance overall. The company reported a significant revenue growth of 62.00% year-on-year, reaching ₹70.34 crores, and a net profit of ₹10.25 crores, which is up 126.27% compared to the same quarter last year. This marks the highest quarterly net sales, operating profit, and profit after tax in the company's history.<BR><BR>The operating margin improved to 26.43%, reflecting effective cost management and operational efficiency. The company has shown robust operational momentum, with a sequential revenue increase of 22.20% as well.<BR><BR>However, while these headline numbers are impressive, there are concerns regarding the company's valuation. Sakar Healthcare is currently trading at a high P/E ratio of 46.66, which is considered "very expensive" compared to its peers. Additionally, the return on equity (ROE) is modest at 6.84%, raising questions about the efficiency of capital deployment despite strong growth.<BR><BR>In summary, while Sakar Healthcare's latest results showcase remarkable growth and operational improvements, the high valuation and modest capital efficiency metrics suggest a more complex investment narrative. Investors should weigh these factors carefully when considering the company's performance and future prospects.

Which are the latest news on Sakar Healthcare?

Should I buy, sell or hold Sakar Healthcare Ltd?

Why is Sakar Healthcare Ltd falling/rising?

As of 11-May, Sakar Healthcare Ltd's stock price is declining, currently at 529.60, reflecting a 2.91% drop. The stock has underperformed significantly over the past week and month, with reduced investor participation contributing to its downward trend.

As of 11-May, Sakar Healthcare Ltd's stock price is falling, currently at 529.60, which reflects a decrease of 15.9 points or 2.91%. This decline is evident in the stock's performance over the past week, where it has underperformed significantly, showing a drop of 18.84% compared to a modest decline of 1.26% in the Sensex. Additionally, the stock has also seen a negative trend over the past month, with a decrease of 10.15%, while the benchmark index fell only by 0.98%.<BR><BR>Investor participation appears to be declining, as indicated by the delivery volume of 42.52 thousand shares on 08 May, which has fallen by 39.92% against the 5-day average. This reduction in trading activity may contribute to the stock's downward pressure. Furthermore, while the stock is currently above its 100-day and 200-day moving averages, it is below the 5-day, 20-day, and 50-day moving averages, suggesting a short-term weakness in price momentum.<BR><BR>Overall, the combination of significant recent losses, reduced investor participation, and underperformance relative to the sector indicates that Sakar Healthcare Ltd's stock is experiencing a downward trend.